Abstract
Description: Two new ruthenium(II) complexes containing guanidinium as ligands, [Ru(dip)2 (L1)]3+ (Ru1) and [Ru(dip)2(L2)]3+ (Ru2) (dip=4,7-diphenyl-1,10-phenanthroline; L1=1-(4-(1H-imidazo[4,5- f][1,10]phenanthrolin-2-yl)phenyl)guanidine cation; L2 = 1-(3-(1H-imidazo[4,5-f][1,10]phenanthrolin-2-yl) phenyl)guanidine cation) have been synthesized and characterized. Both complexes display higher cytotoxicity against several cancer cell lines compared to cisplatin and are less cytotoxic on the nontumorigenic cell line LO2. Intracellular distribution studies show that these complexes are selectively localized in the cytoplasm.
Findings: Further analysis revealed that Ru1 and Ru2 had no obvious effects on the cell cycle and induced apoptosis in HeLa cells via the mitochondrial pathway, which involved reactive oxygen species (ROS) accumulation, mitochondrial dysfunction, and Bcl-2 family member activation. Taken together, the two complexes have the potential to be utilized as anticancer agents.
Keywords: Synthesis, Ru(II) complexes, cytotoxicity, apoptosis, protein, tumor cell.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis, Characterization, and Inducing Tumor Cell Apoptosis of Two Ru(II) Complexes Containing Guanidinium as Ligands
Volume: 18 Issue: 1
Author(s): Jing Sun*, Wen-Xiu Chen, Xing-Dong Song, Shu-Fen He, Jia-Xi Chen, Jun Mei, Xiao-Xian Zhu and Tie Wu
Affiliation:
- School of Pharmacy, Guangdong Medical University, Dongguan, 523808,China
Keywords: Synthesis, Ru(II) complexes, cytotoxicity, apoptosis, protein, tumor cell.
Abstract: Description: Two new ruthenium(II) complexes containing guanidinium as ligands, [Ru(dip)2 (L1)]3+ (Ru1) and [Ru(dip)2(L2)]3+ (Ru2) (dip=4,7-diphenyl-1,10-phenanthroline; L1=1-(4-(1H-imidazo[4,5- f][1,10]phenanthrolin-2-yl)phenyl)guanidine cation; L2 = 1-(3-(1H-imidazo[4,5-f][1,10]phenanthrolin-2-yl) phenyl)guanidine cation) have been synthesized and characterized. Both complexes display higher cytotoxicity against several cancer cell lines compared to cisplatin and are less cytotoxic on the nontumorigenic cell line LO2. Intracellular distribution studies show that these complexes are selectively localized in the cytoplasm.
Findings: Further analysis revealed that Ru1 and Ru2 had no obvious effects on the cell cycle and induced apoptosis in HeLa cells via the mitochondrial pathway, which involved reactive oxygen species (ROS) accumulation, mitochondrial dysfunction, and Bcl-2 family member activation. Taken together, the two complexes have the potential to be utilized as anticancer agents.
Export Options
About this article
Cite this article as:
Sun Jing*, Chen Wen-Xiu, Song Xing-Dong , He Shu-Fen, Chen Jia-Xi, Mei Jun, Zhu Xiao-Xian and Wu Tie , Synthesis, Characterization, and Inducing Tumor Cell Apoptosis of Two Ru(II) Complexes Containing Guanidinium as Ligands, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (1) . https://dx.doi.org/10.2174/1871520617666170419122056
DOI https://dx.doi.org/10.2174/1871520617666170419122056 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Methods in Cytotoxicity Testing: A Review
Recent Patents on Materials Science Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Aptamers Biosensors for Pharmaceutical Compounds
Combinatorial Chemistry & High Throughput Screening Biological Denitrification: Screening of Packing Material, Comparison of Denitrification Rate by Pseudomonas aeruginosa and Pseudomonas stutzeri, Application and Design of Bioreactor
Current Environmental Engineering Impact of Immunogenetic Polymorphisms in Bone Marrow Failure Syndromes
Mini-Reviews in Medicinal Chemistry Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Advances in Nutritional Metabolomics
Current Metabolomics Current Perspective in Cancer Theranostics Based on Gold Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Anti-inflammatory Effect of Predimenol, A Bioactive Extract from <i>Phaleria macrocarpa</i>, through the Suppression of NF-κB and COX-2
Recent Advances in Inflammation & Allergy Drug Discovery Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Current Perspectives on Novel Drug Delivery Systems and Approaches for Management of Cervical Cancer: A Comprehensive Review
Current Drug Targets Advances in Zymography Techniques and Patents Regarding Protease Analysis
Recent Patents on Biotechnology Retinoic Acid Signaling in P19 Stem Cell Differentiation
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Polynuclear Complexes with an Amino Acid or a Peptide as a Bridging Ligand
Current Chemical Biology Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine
Anti-Cancer Agents in Medicinal Chemistry Neonatal Germ Cell Tumors
Current Pediatric Reviews Advances in Bioconjugation
Current Organic Chemistry Potential for Predicting Toxicity and Response of Fluoropyrimidines in Patients
Current Drug Targets